KZIA: Gunggung dhuwit awis saben saham Kazia Therapeutics Ltd

Lambang korporat lan logo Kazia Therapeutics Ltd (KZIA)

The cash per share chart compares the R&D potential of Kazia Therapeutics (KZIA) in developing small molecules for the brain with its current liquidity. The value of 3.31 characterizes this level, confirming the monetization of patents within a narrow niche. This supports the strategy of scaling international trials for targeted programs, providing a financial buffer for the future commercial launch of drugs.

KZIA: Dhuwit awis saben saham kaziatherapeutics.com 04.07.2022 - 21.11.2026

Rincian analitis perusahaan Kazia Therapeutics

Ringkesan analisis perusahaan:KZIA, Kazia Therapeutics Ltd
Produk asli Kazia Therapeutics

A fundamental valuation of Kazia Therapeutics (KZIA) requires a liquidity analysis to determine the business's margin of safety. This indicator calculates the amount of available cash per share, reflecting the actual value of the liquid asset. By analyzing fluctuations in the cash position per share, an investor can discern the burn rate. For Kazia Therapeutics, this is critical while awaiting the results of brain cancer therapy trials. A sufficient cash balance guarantees the completion of research before further dilution becomes necessary.